We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sixteen drugmakers have signed on for a major initiative by the National Institutes of Health to speed the development of COVID-19 therapies and vaccines. Read More
The European Union has drafted a resolution calling on the World Health Organization to create a shared pool of intellectual property rights for vaccines and treatments during the coronavirus pandemic. Read More
Reports of positive early results from a COVID-19 trial of Gilead’s antiviral drug remdesivir in Chicago are premature, according to the University of Chicago Medicine and Biological Sciences. Read More
As the desperate search for a COVID-19 treatment continues, two phase 3 trials in China of Gilead’s remdesivir as a treatment have been suspended due to the lack of eligible patients. Meanwhile, multiple trials of the drug in the U.S. and Europe are going forward. Read More